Switch theme
Sign up to access all valuation multiples
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
1931
38K+
LTM Revenue $11.0B
LTM EBITDA $2.4B
$24.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Baxter International has a last 12-month revenue (LTM) of $11.0B and a last 12-month EBITDA of $2.4B.
In the most recent fiscal year, Baxter International achieved revenue of $10.6B and an EBITDA of $1.1B.
Baxter International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Baxter International valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.0B | XXX | $10.6B | XXX | XXX | XXX |
| Gross Profit | $4.7B | XXX | $4.0B | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 37% | XXX | XXX | XXX |
| EBITDA | $2.4B | XXX | $1.1B | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $1.6B | XXX | $439M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $1.1B | XXX | -$649M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | -6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $11.4B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Baxter International's stock price is $31.
Baxter International has current market cap of $16.0B, and EV of $24.0B.
See Baxter International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24.0B | $16.0B | XXX | XXX | XXX | XXX | $2.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Baxter International has market cap of $16.0B and EV of $24.0B.
Baxter International's trades at 2.3x EV/Revenue multiple, and 21.5x EV/EBITDA.
Equity research analysts estimate Baxter International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Baxter International has a P/E ratio of 14.2x.
See valuation multiples for Baxter International and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.0B | XXX | $16.0B | XXX | XXX | XXX |
| EV (current) | $24.0B | XXX | $24.0B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 10.2x | XXX | 21.5x | XXX | XXX | XXX |
| EV/EBIT | 14.8x | XXX | 54.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.2x | XXX | -24.7x | XXX | XXX | XXX |
| EV/FCF | 22.0x | XXX | 43.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBaxter International's last 12 month revenue growth is 6%
Baxter International's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Baxter International's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Baxter International's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Baxter International and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Baxter International acquired XXX companies to date.
Last acquisition by Baxter International was XXXXXXXX, XXXXX XXXXX XXXXXX . Baxter International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Baxter International founded? | Baxter International was founded in 1931. |
| Where is Baxter International headquartered? | Baxter International is headquartered in United States of America. |
| How many employees does Baxter International have? | As of today, Baxter International has 38K+ employees. |
| Who is the CEO of Baxter International? | Baxter International's CEO is Mr. D. Brent Shafer. |
| Is Baxter International publicy listed? | Yes, Baxter International is a public company listed on NYS. |
| What is the stock symbol of Baxter International? | Baxter International trades under BAX ticker. |
| When did Baxter International go public? | Baxter International went public in 1961. |
| Who are competitors of Baxter International? | Similar companies to Baxter International include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Baxter International? | Baxter International's current market cap is $16.0B |
| What is the current revenue of Baxter International? | Baxter International's last 12 months revenue is $11.0B. |
| What is the current revenue growth of Baxter International? | Baxter International revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Baxter International? | Current revenue multiple of Baxter International is 2.2x. |
| Is Baxter International profitable? | Yes, Baxter International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Baxter International? | Baxter International's last 12 months EBITDA is $2.4B. |
| What is Baxter International's EBITDA margin? | Baxter International's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Baxter International? | Current EBITDA multiple of Baxter International is 10.2x. |
| What is the current FCF of Baxter International? | Baxter International's last 12 months FCF is $1.1B. |
| What is Baxter International's FCF margin? | Baxter International's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Baxter International? | Current FCF multiple of Baxter International is 22.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
